Medical Director Articles

The term "article" is used to describe any bulletin article, web site article, educational handout or any other non-LCD document intended for public release that contains coverage/coding statements or medical review related billing or claims considerations.

Articles address local coverage, coding or medical review related billing and claims considerations, and may include any newly developed educational materials, coding instructions or clarification of existing medical review related billing or claims policy.

The article listing will continue to expand as additions are made.

Last Updated Jan 30 , 2024
Articles Source Posted
MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules (L39682) - R1 - Effective March 13, 2025 Mar 14, 2025
MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia (L39262) - R1 - Effective March 13, 2025 Mar 14, 2025
MolDX: Plasma-Based Genomic Profiling in Solid Tumors (L39230) - R1 - Effective March 6, 2025 Mar 07, 2025
Intervertebral Disc Repair Final LCD - Effective April 13, 2025 Feb 27, 2025
Policy Revision(s) for Local Coverage Determinations - Effective February 14, 2025 Feb 20, 2025
Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) - Published for Review and Comments Feb 10, 2025
Open Public Meeting Announcement - Allergy Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) - March 6, 2025 Feb 10, 2025
Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58454) - R9 - Effective November 18, 2024 Feb 10, 2025
MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (L39001) - R3 - Effective January 30, 2025 Feb 06, 2025
Billing and Coding: Hypoglossal Nerve Stimulation for Treatment of Obstructive Sleep Apnea (A57948) - R4 - Effective December 1, 2024 Jan 30, 2025
Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (A58720)- R23 - Effective January 1, 2025 Jan 23, 2025
Billing and Coding: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer (A58718)- R5 - Effective September 11, 2024 Jan 23, 2025
Billing and Coding: Diagnostic and Therapeutic Colonoscopy (A57342)- R6 - Effective October 1, 2024 Jan 17, 2025
Billing and Coding: MolDX: Plasma-Based Genomic Profiling in Solid Tumors (A58973)- R6 - Effective January 1, 2025 Jan 16, 2025
Billing and Coding: MolDX: Molecular Diagnostic Tests (MDT) (A57526)- R21 - Effective January 1, 2025 Jan 16, 2025
Billing and Coding: Trigger Point Injections (TPI) (A57701) - R6 - Effective April 1, 2024 Jan 16, 2025
Billing and Coding: Cervical Fusion (A59624) - R3 - Effective July 7, 2024 Jan 16, 2025
Multi-Jurisdictional CAC Meeting Announcement - Peripheral Nerve Blocks - February 3, 2025, 2 - 4 p.m. ET Jan 13, 2025
Multi-Jurisdictional Contractor Advisory Committee (CAC) Peripheral Nerve Blocks - Key Questions and References Jan 13, 2025
Multi-Jurisdictional Peripheral Nerve Blocks Contractor Advisory Committee (CAC) Meeting Agenda Jan 13, 2025